Survodutide

WHAT IT IS

Survodutide is an engineered peptide, not a naturally occurring hormone, built to bind and activate two separate receptors: the glucagon receptor and the receptor for glucagon-like peptide-1 (GLP-1). This dual-agonist design places it in the same broad family of research as tirzepatide and retatrutide, though each of those compounds combines a different pair of receptor activities.

It is being developed under the code name BI 456906 through a partnership between Boehringer Ingelheim and Zealand Pharma, and it has advanced into large, multi-phase human trials.

It is an investigational drug candidate. It has not received FDA approval for any indication, and any product sold outside of a regulated clinical trial or pharmacy channel is not a verified, approved medicine.

WHAT RESEARCHERS ARE STUDYING IT FOR

Published and registered human trials have examined survodutide for:

• Weight management in adults with obesity or overweight
• Type 2 diabetes and glycemic control
• Metabolic dysfunction-associated steatohepatitis (MASH), formerly called NASH
• Liver fat content and markers of liver fibrosis
• Broader metabolic markers such as blood pressure and lipid levels alongside weight change

PROPOSED BIOLOGICAL MECHANISMS

GLP-1 receptor activation slows gastric emptying, increases feelings of fullness and supports insulin release in response to food, mechanisms shared with approved GLP-1 medicines such as semaglutide.

Glucagon receptor activation is different. Glucagon is usually thought of as raising blood sugar, but at the level of energy metabolism it can increase energy expenditure and promote fat breakdown in the liver, which is the rationale for pairing it with a GLP-1 effect that also reduces intake.

The hypothesis behind dual agonism is that combining an appetite-and-glucose effect with an energy-expenditure effect could produce more weight loss and more improvement in liver fat than a GLP-1 medicine alone, though whether that combination proves safer or more effective long term is still being established.

AREAS OF RESEARCH INTEREST

• Whether the added glucagon activity produces meaningfully greater weight loss than GLP-1-only medicines
• Whether the drug's effects on liver fat and inflammation translate to improved MASH outcomes
• The long-term tolerability of combined glucagon and GLP-1 receptor activation
• How survodutide's effect sizes and side-effect profile compare with tirzepatide and semaglutide

WHAT THE EVIDENCE CURRENTLY SUGGESTS

Survodutide has advanced further in human testing than most compounds covered in this library. Phase 2 trials published in peer-reviewed journals reported meaningful weight loss in adults with obesity and improvements in liver fat and fibrosis markers in people with MASH, with effects that generally increased with higher doses.

Gastrointestinal side effects, including nausea, vomiting and diarrhea, were the most commonly reported adverse events, consistent with other incretin-based therapies, and some participants discontinued treatment because of them.

Phase 3 trials are underway to confirm these findings in larger, longer populations. FDA status: survodutide is an investigational drug and is not currently FDA-approved for any condition.